Navigation Links
Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
Date:1/24/2010

d neutropenia; complications were rare, with only 1 patient (2 percent) having febrile neutropenia and 2 patients (4 percent) having minor bleeding issues.
  • Most other toxicities, including gastrointestinal toxicity, were similar for both regimens except for alopecia, which was more frequent with FOLPI.

  • About Picoplatin

    Picoplatin is a new and differentiated platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration.  It is designed to overcome platinum resistance associated with chemotherapy in solid tumors.  Study data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies and can be safely administered in combination with multiple approved oncology products.  Approximately 1,100 patients have received picoplatin.  Results obtained to date suggest that hematologic events are common but manageable.  Kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) are less frequent and less severe than is commonly observed with other platinum chemotherapy drugs.  Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors.

    In addition to the Phase 2 clinical trial of picoplatin in patients with metastatic CRC, Poniard has evaluated intravenous picoplatin in the treatment of small cell lung cancer in its Phase 3 SPEAR trial.  This trial did not meet its primary endpoint of overall survival, and the Company plans to meet with the FDA to discuss a potential regulatory path forward for picoplatin in this indication.  Poniard is also evaluating picoplatin in a Phase 2 clinical trial in patients with metastatic hormone-refractory prostate cancer.  Final results of the Company's Phase 1 cardiac safety trial and the Phase 1 trial of an oral formulation of picoplatin were presented in
    '/>"/>

    SOURCE Poniard Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
    2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
    3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
    4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
    5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
    6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
    7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
    8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
    9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
    10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
    11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/21/2014)...  Edwards Lifesciences Corporation (NYSE: EW ), ... and hemodynamic monitoring, announced today that it will increase ... strong launch of Edwards Lifesciences Foundation,s new charitable initiative, ... global communities where its employees live and work. ... exceed $8 million, including more than $7 million in ...
    (Date:11/21/2014)... , Nov. 20, 2014 /CNW Telbec/ - KLOX Technologies ... the following appointments: Todd Martensen ... the newly created role of Chief Commercial Officer, to ... using topical photoconverter gel for the treatment of chronic ... traumatic wounds, recently approved in Europe ...
    (Date:11/21/2014)... , Nov. 20, 2014   Coqui RadioPharmaceuticals ... the first U.S. commercial producer of Molybdenum-99 (Mo-99), is ... with INVAP to design its Medical Isotope ... Mo-99 is the parent isotope of Technetium-99, which ... worldwide. In 2012, Congress passed legislation making it a ...
    Breaking Medicine Technology:Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Coqui RadioPharmaceuticals Inks Deal With INVAP 2
    (Date:11/23/2014)... 2014 Wright & Schulte LLC recently ... and West Virginia residents who allege that they developed ... due to drinking C8 contaminated water released by ... According to the C8 complaints, the plaintiffs were exposed ... lived in at least one of the six water ...
    (Date:11/22/2014)... Every year AlignLife clinics nationwide team together to ... in the Greenville, SC area in 2014 and has ... Simpsonville will be partnering with the 5 other ... Drive. These six offices came together to decide on ... toy drive. With so many amazing organizations to choose ...
    (Date:11/22/2014)... PrettyTailor , an outstanding dress company, has ... Customers can buy new dresses at its online shop ... website. , As a matter of fact, PrettyTailor specializes ... provides four types of wedding outfits, including bridesmaid dresses, ... It also provides a variety of occasion dresses, such ...
    (Date:11/22/2014)... November 23, 2014 Recently, Locks-Magnetic.com ... introduced a new promotion of mag locks for glass ... an attracting discount on these fresh products. Customers can ... locks for glass doors are in excellent performance. Customers ... the website as soon as possible. They also ...
    (Date:11/22/2014)... Setria® Glutathione is now available ... for use “as a therapeutically active ingredient in ... Therapeutic Goods (Listing) Notice 2014 (No. 5) - ... Glutathione will be exclusivity distributed in Australia by ... imports fine chemicals to Australian manufacturers. TGA approval ...
    Breaking Medicine News(10 mins):Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 3Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 4Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Discounted Mag Locks for Glass Doors Revealed by Locks-Magnetic.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
    ... children are far more likely to receive cranial computed ... head trauma than are African-American or Hispanic children, a ... The study findings do not indicate that CT scans ... researchers said. Rather, they suggest that white children may ...
    ... -- Fewer than half of U.S. children injured in car ... minority children had the lowest rates of seat-belt use, a ... involving nearly 40,000 children under age 16 and found that ... had the lowest rates of seat-belt use. The overall ...
    ... BOSTON Sports-related knee injuries in children and adolescents seem ... the Children,s Hospital of Philadelphia noted a more than 400 ... last decade, according to new research presented on Sunday, Oct. ... and Exhibition in Boston. In "Knee Injuries In ...
    ... Maternal Health Advocate Christy Turlington Burns will speak at ... Child Health meeting at the AAP National Conference & ... p.m. ET. Ms. Turlington Burns is the founder of ... 2010 to increase public awareness of and support for ...
    ... treatment beyond two days was linked to an ... formation; longer hospitalization; increased costs; and more rarely, ... at the American Academy of Pediatrics (AAP) National ... Opportunities in the Treatment of Pediatric Appendicitis," researchers ...
    ... Dennis Thompson HealthDay Reporter , FRIDAY, Oct. 14 ... recent years by becoming more and more personalized. Not ... tumors and cancer cells inside that patient. New tests ... factors are driving each individual woman,s type of cancer, and ...
    Cached Medicine News:Health News:White children far more likely to receive CT scans than Hispanic, African-American children 2Health News:Fewer Than Half of Kids Hurt in Car Crashes Wearing Seat Belts 2Health News:Knee injuries on the rise in child and adolescent athletes 2Health News:Delayed pediatric appendicitis treatment linked to complications, and even death 2Health News:Genetic Profiling Adds New Dimension to Breast Cancer Treatment 2Health News:Genetic Profiling Adds New Dimension to Breast Cancer Treatment 3
    Reservoir, Low Profile, Single Well, Flat Bottom, 90mL Available Sterile...
    Reservoir, High Profile, Single Well, 12 Row, Pyramid Bottom Available Sterile...
    ... applications or for use in an automated ... eight-port disposable manifold provides greater ease, speed, ... The StatMatic II can be connected to ... completely fill a microplate with one-handed operation ...
    ... has created this extremely versatile and efficient ... liquid handling. With EDOS, high sample throughput ... with ease. ,The smallest volume that ... corresponding Combitip. The easy-to-follow user menus presented ...
    Medicine Products: